Syracuse University researchers are making strides in understanding the disease
mechanism of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Not exact matches
Scientists have identified the molecular
mechanism that leads to the death
of neurons in
amyotrophic lateral sclerosis (also known as ALS or motor neurone disease) and a common form
of frontotemporal dementia.
A team
of scientists led by Gladstone's Dr. Steven Finkbeiner have identified a cellular
mechanism that can be targeted to treat
amyotrophic lateral sclerosis (ALS).
It took eight long years
of research, but now an international team led by neuroscientists at Université de Montréal has discovered a basic molecular
mechanism that better helps understand how Lou Gehrig's disease, or
amyotrophic lateral sclerosis (ALS), works.
Core areas
of research at the institute include work on brain - computer interfaces to aid patients with spinal injury and paralysis; innovative advances in computational neuroscience to address behavior and mood disorders; and research into
mechanisms of cell death as part
of efforts to identify therapies for neurodegenerative diseases that include
amyotrophic lateral sclerosis (ALS) and Alzheimer's.